0001104659-21-145951.txt : 20211202
0001104659-21-145951.hdr.sgml : 20211202
20211202170027
ACCESSION NUMBER: 0001104659-21-145951
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211130
FILED AS OF DATE: 20211202
DATE AS OF CHANGE: 20211202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Yang Arvin
CENTRAL INDEX KEY: 0001834321
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38129
FILM NUMBER: 211467542
MAIL ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mersana Therapeutics, Inc.
CENTRAL INDEX KEY: 0001442836
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-498-0020
MAIL ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: MERSANA THERAPEUTICS INC
DATE OF NAME CHANGE: 20080813
4
1
tm2134477-1_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-11-30
0
0001442836
Mersana Therapeutics, Inc.
MRSN
0001834321
Yang Arvin
C/O MERSANA THERAPEUTICS, INC.
840 MEMORIAL DRIVE
CAMBRIDGE
MA
02139
0
1
0
0
Chief Medical Officer
Common Stock
2021-11-30
4
M
0
18500
A
18500
D
Common Stock
2021-12-01
4
S
0
5527
6.81
D
12973
D
Restricted Stock Units
2021-11-30
4
M
0
18500
0
D
Common Stock
18500
18500
D
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon settlement.
Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs listed in Table II. These sales were mandated by the Issuer's election under its equity incentive plans to require the reporting person to sell a number of shares of common stock needed to satisfy his tax withholding obligations and does not represent a discretionary trade by the reporting person.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $6.68 to $7.00, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any security holder of Mersana Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
50% of the total number of RSUs vested on November 30, 2021, and the remainder of the total number of RSUs shall vest on November 30, 2022.
Brian DeSchuytner, as Attorney-in-Fact
2021-12-02